(CercleFinance.com) – The group announces that neoadjuvant Opdivo (nivolumab) combined with chemotherapy offers benefits to patients with resectable non-small cell lung cancer with three-year follow-up in the CheckMate -816 trial.
These results will be presented in a late-breaking oral presentation at the European Society for Medical Oncology (ESMO) 2023 Congress on October 23, 2023.
‘Encouragingly, this neoadjuvant immunotherapy combination demonstrated improvements in all efficacy measures, regardless of PD-L1 expression levels. The CheckMate -816 data clearly indicates the potential for better patient outcomes with this regimen than chemotherapy alone,’ said Mariano Provencio Pulla, MD, Ph.D., Medical Oncology, Puerta de Hierro University Hospital, Madrid, Spain.
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends using the buttons below.
